Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727526 | 0.89 | — | — | |
| SCHEMBL5336349 | 0.88 | — | — | |
| SCHEMBL5344098 | 0.78 | THRA (0.37) | ACHETHRATHRB | |
| SCHEMBL2414771 | 0.77 | MAOA (0.32) | THRATHRB | |
| SCHEMBL2423359 | 0.76 | CYP24A1 (0.31) | ACHETHRATHRB | |
| SCHEMBL2419510 | 0.76 | MEN1 (0.31) | — | |
| SCHEMBL2416248 | 0.76 | HTR2A (0.32) | ACHE | |
| SCHEMBL2421172 | 0.76 | HTR1A (0.33) | — | |
| SCHEMBL7065887 | 0.73 | SIRT2 (0.43) | THRATHRB | |
| SCHEMBL2413944 | 0.72 | ACHE (0.38) | ACHETHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157604-B2 | Selective estrogen receptor modulators | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157604-B2 | Selective estrogen receptor modulators | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157604-B2 | Selective estrogen receptor modulators | MERCK & CO., INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1418900-A4 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20040210080-A1 | Selective estrogen receptor modulators | MERCK & CO., INC. | 2004-10-21 | — | — | US | disclosed |
| EP-1418900-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003015761-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210080-A1 | Selective estrogen receptor modulators | GPER1, ESR2, ESR1 | ACHE 1176/4885THRA 497/4885THRB 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.